Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by WILLIAM G WIERDA and NITIN JAIN.
WILLIAM G WIERDA
Connection Strength
11.322
NITIN JAIN
  1. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Adv. 2023 05 23; 7(10):1958-1966.
    View in: PubMed
    Score: 0.897
  2. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol. 2021 Aug 01; 7(8):1213-1219.
    View in: PubMed
    Score: 0.791
  3. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia. 2021 12; 35(12):3421-3429.
    View in: PubMed
    Score: 0.780
  4. Ibrutinib and Venetoclax for First-Line Treatment of CLL. Reply. N Engl J Med. 2019 08 22; 381(8):789.
    View in: PubMed
    Score: 0.691
  5. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019 05 30; 380(22):2095-2103.
    View in: PubMed
    Score: 0.681
  6. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. Oncotarget. 2017 Mar 28; 8(13):22104-22112.
    View in: PubMed
    Score: 0.585
  7. Chronic lymphocytic leukaemia. Lancet. 2024 Aug 17; 404(10453):694-706.
    View in: PubMed
    Score: 0.243
  8. Venetoclax consolidation in high-risk CLL treated with ibrutinib for =1 year achieves a high rate of undetectable MRD. Leukemia. 2023 07; 37(7):1444-1453.
    View in: PubMed
    Score: 0.223
  9. TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis. Am J Hematol. 2022 08; 97(8):1005-1012.
    View in: PubMed
    Score: 0.209
  10. Acalabrutinib in treatment-naive chronic lymphocytic leukemia. Blood. 2021 06 17; 137(24):3327-3338.
    View in: PubMed
    Score: 0.196
  11. Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia. Br J Haematol. 2021 07; 194(1):61-68.
    View in: PubMed
    Score: 0.195
  12. Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood. 2019 11 28; 134(22):1951-1959.
    View in: PubMed
    Score: 0.176
  13. The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. Br J Haematol. 2019 10; 187(1):e1-e4.
    View in: PubMed
    Score: 0.172
  14. Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol. 2019 11; 187(3):307-318.
    View in: PubMed
    Score: 0.171
  15. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol. 2019 06; 185(5):852-864.
    View in: PubMed
    Score: 0.168
  16. Distinguishing thymoma from T-lymphoblastic leukaemia/lymphoma: a case-based evaluation. J Clin Pathol. 2019 Mar; 72(3):251-257.
    View in: PubMed
    Score: 0.164
  17. A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia. Br J Haematol. 2019 05; 185(3):606-608.
    View in: PubMed
    Score: 0.164
  18. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia. 2018 11; 32(11):2388-2398.
    View in: PubMed
    Score: 0.157
  19. Co-occurrence of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients. Haematologica. 2017 12; 102(12):e514-e517.
    View in: PubMed
    Score: 0.151
  20. Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemia-A case report. Hematol Oncol Stem Cell Ther. 2019 Sep; 12(3):161-165.
    View in: PubMed
    Score: 0.150
  21. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer. 2017 Jun 15; 123(12):2268-2273.
    View in: PubMed
    Score: 0.145
  22. PET-positive lymphadenopathy in CLL-Not always Richter transformation. Am J Hematol. 2017 04; 92(4):405-406.
    View in: PubMed
    Score: 0.145
  23. Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab. Hematol Oncol Stem Cell Ther. 2017 Sep; 10(3):151-154.
    View in: PubMed
    Score: 0.139
  24. ?2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. Cancer. 2016 Feb 15; 122(4):565-73.
    View in: PubMed
    Score: 0.133
  25. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica. 2014 Aug; 99(8):1350-5.
    View in: PubMed
    Score: 0.120
  26. A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia. Cancer. 2009 Oct 01; 115(19):4533-9.
    View in: PubMed
    Score: 0.087
  27. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer. 2024 Nov 25.
    View in: PubMed
    Score: 0.062
  28. The DLEU2/miR-15a/miR-16-1 cluster shapes the immune microenvironment of chronic lymphocytic leukemia. Blood Cancer J. 2024 10 23; 14(1):168.
    View in: PubMed
    Score: 0.062
  29. Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV, ZAP-70, and MRD. Blood. 2024 Oct 23.
    View in: PubMed
    Score: 0.062
  30. Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma. Leukemia. 2024 Dec; 38(12):2717-2721.
    View in: PubMed
    Score: 0.062
  31. LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclax-resistant chronic lymphocytic leukemia. Haematologica. 2024 Aug 08.
    View in: PubMed
    Score: 0.061
  32. Effect of Digital Health Coaching on Self-Efficacy and Patient-Reported Outcomes in Individuals with Acute Myeloid and Chronic Lymphocytic Leukemia: A Pilot Randomized Controlled Trial. Acta Haematol. 2024 Jun 11; 1-10.
    View in: PubMed
    Score: 0.060
  33. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia. Blood Adv. 2024 05 28; 8(10):2342-2350.
    View in: PubMed
    Score: 0.060
  34. Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study. J Clin Oncol. 2024 Jun 10; 42(17):2071-2079.
    View in: PubMed
    Score: 0.059
  35. A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia. Blood Adv. 2024 02 27; 8(4):909-915.
    View in: PubMed
    Score: 0.059
  36. ZNF683 marks a CD8+ T?cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome. Cancer Cell. 2023 10 09; 41(10):1803-1816.e8.
    View in: PubMed
    Score: 0.057
  37. Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation. Leuk Lymphoma. 2023 09; 64(9):1554-1561.
    View in: PubMed
    Score: 0.056
  38. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol. 2023 Jun; 10(6):e433-e444.
    View in: PubMed
    Score: 0.056
  39. Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity. Cancer. 2023 07 15; 129(14):2192-2200.
    View in: PubMed
    Score: 0.056
  40. Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma?variant. Virchows Arch. 2023 Jun; 482(6):1011-1019.
    View in: PubMed
    Score: 0.055
  41. Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma. Pathology. 2023 Jun; 55(4):514-524.
    View in: PubMed
    Score: 0.055
  42. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Nat Med. 2023 01; 29(1):158-169.
    View in: PubMed
    Score: 0.055
  43. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol. 2023 03; 98(3):493-501.
    View in: PubMed
    Score: 0.055
  44. STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells. J Immunol. 2022 06 15; 208(12):2847-2855.
    View in: PubMed
    Score: 0.052
  45. Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia. Leuk Res. 2022 05; 116:106827.
    View in: PubMed
    Score: 0.052
  46. Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. Am J Hematol. 2022 06 01; 97(6):E201-E204.
    View in: PubMed
    Score: 0.052
  47. Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors. Leuk Lymphoma. 2022 04; 63(4):885-893.
    View in: PubMed
    Score: 0.051
  48. Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia. Front Oncol. 2022; 12:833714.
    View in: PubMed
    Score: 0.051
  49. Non-coding NOTCH1 mutations in chronic lymphocytic leukemia negatively impact prognosis. Am J Hematol. 2022 03 01; 97(3):E100-E102.
    View in: PubMed
    Score: 0.051
  50. Ibrutinib induces durable remissions in treatment-na?ve patients with CLL and 17p deletion and/or TP53 mutations. Blood. 2021 12 16; 138(24):2589-2592.
    View in: PubMed
    Score: 0.051
  51. Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. Leuk Lymphoma. 2022 03; 63(3):672-675.
    View in: PubMed
    Score: 0.050
  52. The cure of leukemia through the optimist's prism. Cancer. 2022 01 15; 128(2):240-259.
    View in: PubMed
    Score: 0.050
  53. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica. 2021 08 01; 106(8):2121-2130.
    View in: PubMed
    Score: 0.049
  54. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer. 2021 08 01; 127(15):2648-2656.
    View in: PubMed
    Score: 0.048
  55. STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells. Oncotarget. 2021 Mar 02; 12(5):401-411.
    View in: PubMed
    Score: 0.048
  56. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J. 2021 02 01; 11(2):25.
    View in: PubMed
    Score: 0.048
  57. CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia. Leukemia. 2021 06; 35(6):1610-1620.
    View in: PubMed
    Score: 0.047
  58. Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib. Blood Adv. 2020 09 22; 4(18):4508-4511.
    View in: PubMed
    Score: 0.047
  59. Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. Leuk Lymphoma. 2021 01; 62(1):224-228.
    View in: PubMed
    Score: 0.047
  60. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia. 2020 11; 34(11):2914-2924.
    View in: PubMed
    Score: 0.046
  61. Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib. Leuk Lymphoma. 2020 10; 61(10):2488-2491.
    View in: PubMed
    Score: 0.046
  62. Treating Leukemia in the Time of COVID-19. Acta Haematol. 2021; 144(2):132-145.
    View in: PubMed
    Score: 0.045
  63. Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol. 2020 07; 95(7):734-739.
    View in: PubMed
    Score: 0.045
  64. Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors. Blood. 2020 02 13; 135(7):510-513.
    View in: PubMed
    Score: 0.045
  65. The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. Leukemia. 2020 06; 34(6):1588-1598.
    View in: PubMed
    Score: 0.044
  66. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol. 2020 02; 95(2):144-150.
    View in: PubMed
    Score: 0.044
  67. STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage. J Immunol. 2019 12 01; 203(11):3078-3085.
    View in: PubMed
    Score: 0.044
  68. First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL). Leuk Lymphoma. 2020 02; 61(2):445-449.
    View in: PubMed
    Score: 0.044
  69. Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Adv. 2019 05 14; 3(9):1533-1539.
    View in: PubMed
    Score: 0.042
  70. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019 03 07; 133(10):1011-1019.
    View in: PubMed
    Score: 0.041
  71. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer. 2019 02 15; 125(4):559-574.
    View in: PubMed
    Score: 0.041
  72. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol. 2018 Dec; 5(12):e618-e627.
    View in: PubMed
    Score: 0.041
  73. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood. 2018 11 22; 132(21):2249-2259.
    View in: PubMed
    Score: 0.041
  74. STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells. Oncotarget. 2018 Sep 14; 9(72):33710-33718.
    View in: PubMed
    Score: 0.041
  75. STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells. Oncotarget. 2018 Apr 20; 9(30):21268-21280.
    View in: PubMed
    Score: 0.039
  76. Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia. Leuk Lymphoma. 2018 11; 59(11):2686-2691.
    View in: PubMed
    Score: 0.039
  77. Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia. Leukemia. 2018 10; 32(10):2278-2281.
    View in: PubMed
    Score: 0.039
  78. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol. 2018 04; 15(4):218.
    View in: PubMed
    Score: 0.039
  79. Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood. 2018 04 19; 131(16):1820-1832.
    View in: PubMed
    Score: 0.039
  80. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018 02; 19(2):240-248.
    View in: PubMed
    Score: 0.039
  81. Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy. Oncoimmunology. 2018; 7(4):e1417720.
    View in: PubMed
    Score: 0.039
  82. Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. Am J Hematol. 2018 03; 93(3):371-374.
    View in: PubMed
    Score: 0.039
  83. The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. Br J Haematol. 2018 01; 180(1):33-40.
    View in: PubMed
    Score: 0.038
  84. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol. 2018 01; 93(1):91-99.
    View in: PubMed
    Score: 0.038
  85. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018 Jan; 15(1):47-62.
    View in: PubMed
    Score: 0.038
  86. Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. Clin Lymphoma Myeloma Leuk. 2017 Dec; 17(12):897-901.
    View in: PubMed
    Score: 0.038
  87. Activation of the B-cell receptor successively activates NF-?B and STAT3 in chronic lymphocytic leukemia cells. Int J Cancer. 2017 11 15; 141(10):2076-2081.
    View in: PubMed
    Score: 0.037
  88. Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens. Am J Hematol. 2017 10; 92(10):E595-E597.
    View in: PubMed
    Score: 0.037
  89. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2018 04; 59(4):813-820.
    View in: PubMed
    Score: 0.037
  90. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer. 2017 Nov 15; 123(22):4430-4439.
    View in: PubMed
    Score: 0.037
  91. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. Cancer. 2017 Oct 01; 123(19):3717-3724.
    View in: PubMed
    Score: 0.037
  92. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer. 2017 Aug 15; 123(16):3050-3060.
    View in: PubMed
    Score: 0.037
  93. Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex. Mol Cancer Res. 2017 05; 15(5):610-618.
    View in: PubMed
    Score: 0.036
  94. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol. 2017 Feb; 4(2):e67-e74.
    View in: PubMed
    Score: 0.036
  95. Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia. J Immunol. 2017 02 15; 198(4):1740-1747.
    View in: PubMed
    Score: 0.036
  96. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017 03 09; 129(10):1275-1283.
    View in: PubMed
    Score: 0.036
  97. Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. J Clin Oncol. 2017 Jan 10; 35(2):166-174.
    View in: PubMed
    Score: 0.036
  98. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 2016 06; 101(6):e254-8.
    View in: PubMed
    Score: 0.034
  99. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2016 Feb; 172(3):392-400.
    View in: PubMed
    Score: 0.033
  100. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015 Nov; 16(15):1547-1555.
    View in: PubMed
    Score: 0.033
  101. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 2015 Oct 15; 121(20):3612-21.
    View in: PubMed
    Score: 0.033
  102. Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells. Mol Cancer Res. 2015 May; 13(5):944-53.
    View in: PubMed
    Score: 0.032
  103. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015 Mar 26; 125(13):2062-7.
    View in: PubMed
    Score: 0.031
  104. Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. Blood. 2014 Jun 12; 123(24):3797-802.
    View in: PubMed
    Score: 0.030
  105. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood. 2014 Jun 12; 123(24):3727-32.
    View in: PubMed
    Score: 0.030
  106. Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood. 2014 May 01; 123(18):2783-90.
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.